Cadrenal Therapeutics, Inc. Common Stock
CVKD
$-0.13
Change (1 day)
$32.55
Year High
$5.40
Year Low
Categories
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Revenue of Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Revenue in 2023 (TTM): $
According to Cadrenal Therapeutics, Inc. Common Stock's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Cadrenal Therapeutics, Inc. Common Stock
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,980 | $-8,338,005 | $-8,357,086 | $-8,357,086 |
| 2022 | $ | $-1,266 | $-6,605,958 | $-6,714,329 | $-6,714,329 |